Viatris Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 0A5V.IL | TEVA | UTHR | MEGA.BK | INDSWFTLAB.NS | 3933.HK | |
|---|---|---|---|---|---|---|
| Market cap | 23.81B | 45.77B | 23.63B | 30.78B | 27.90B | 13.57B |
| P/E (TTM) | 13.0 | 91.2 | 20.9 | 13.4 | 32.8 | 25.5 |
| Forward P/E | — | 12.5 | 17.4 | 12.5 | — | 9.9 |
| Price/book | 1.1 | 5.7 | 3.7 | 3.0 | 1.9 | 0.7 |
| Dividend yield | 5.13% | — | — | 4.72% | — | 4.18% |
| 1-year change | +99.81% | +58.38% | +17.75% | +16.13% | +231.23% | −39.10% |
| Today | −1.51% | +1.79% | −0.78% | −1.94% | −4.38% | −3.71% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 0A5V.IL news ›Viatris Finalizes $1.69 Billion Acquisition of Pacira BioSciences via Tender Offer and Merger
Make Kalkine Media My Trusted Source On November 17, 2026, Viatris Inc. announced through a Form 8-K filing the successful completion of its acquisition of Pacira BioSciences, Inc., finalized via a tender offer and subsequent merger on the…
Q3 earnings highs and lows: Viatris vs the rest of the generic pharmaceuticals stocks
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer. StockStory - Wed Nov 18, 9:31PM CST The end of an earnings…
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Transcripts Viatris Inc. (VTRS) Jefferies Global Healthcare Conference 2026 November 18, 2026 4:00 AM EST Scott Smith - CEO & Director Paul Campbell - Interim CFO, Chief Accounting Officer & Corporate Controller Philippe Martin - Chief R&D…
Viatris Completes Acquisition Of Pacira BioSciences For $36.50 Per Share
Viatris has completed its acquisition of Pacira BioSciences, expanding its U.S. innovative medicines business and establishing a larger position in non-opioid pain management. The transaction, originally announced on October 8, 2026, was…
Viatris Completes Acquisition of Pacira BioSciences, Expanding Pain Management Portfolio
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Diclofenac Sodium Viatris (formerly Fenac)
This leaflet answers some common questions about DICLOFENAC SODIUM VIATRIS. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. NOTICE: This Consumer Medicine…
Viatris Completes Pacira Acquisition
Viatris said Tuesday it has completed its acquisition of Pacira BioSciences , a non-opioid pain management firm, following a tender offer at $36.50 per share. The company said about 66.5% of shares... Viatris Completes Pacira Acquisition…
Oppenheimer Adjusts Price Target on Viatris to $26 From $25, Maintains Outperform Rating
Viatris has an average rating of overweight and mean price target of $22, according to analysts polled by FactSet. Oppenheimer Adjusts Price Target on Viatris to $26 From $25, Maintains Outperform Rating This super rating is the result of…
Viatris Inc. completed the acquisition of Pacira BioSciences, Inc..
Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Pacira BioSciences, Inc. (NasdaqGS:PCRX) for $1.6 billion on October 8, 2026. Under the terms of the transaction, Viatris ... Viatris Inc. completed the…
More from 1 other outlet
Viatris Closes $1.65 Billion Pacira Deal for Non-Opioid Pain Medicines
Biotechnology Add Securities.io to your preferred sources on Google Key PointsViatris gains two marketed non-opioid pain medicines plus a Phase 2 gene therapy… View more Viatris gains two marketed non-opioid pain medicines plus a Phase 2…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com12
- seekingalpha.com8
- prnewswire.com6
- quantisnow.com3
- tradingview.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 50 articles, not a forecast.